Correspondingly, the Alzheimer’s Association Workgroup recently proposed a biomarker-based diagnostic framework, where abnormal Core 1 biomarkers (amyloid PET, approved CSF, and ‘accurate’ plasma biomarkers; e.g. plasma p-tau217) are sufficient to diagnose Alzheimer’s disease in the absence of symptoms, whereas abnormal Core 2 biomarkers (e.g. tau PET), presumed to change later in disease and to be more temporally proximal to symptoms, can provide prognostic information and increase confidence that Alzheimer’s disease is contributing to symptoms. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.